KALV
Kalvista Pharmaceuticals Inc
$
12.510
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
12.530
Open
12.370
VWAP
12.41
Vol
449.80K
Mkt Cap
624.92M
Low
12.250
Amount
5.58M
EV/EBITDA(TTM)
--
Total Shares
42.19M
EV
505.19M
EV/OCF(TTM)
--
P/S(TTM)
--
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
--
--
-0.959
+10.2%
--
--
-0.901
-0.96%
--
--
-0.836
-9.1%
Estimates Revision
The market is revising Upward the revenue expectations for KalVista Pharmaceuticals, Inc. (KALV) for FY2026, with the revenue forecasts being adjusted by 12.19% over the past three months. During the same period, the stock price has changed by 2.71%.
Revenue Estimates for FY2026
Revise Upward
+12.19%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
+11.57%
In Past 3 Month
Stock Price
Go Up
+2.71%
In Past 3 Month
9 Analyst Rating
153.16% Upside
Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is 31.67 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
153.16% Upside
Current: 12.510
Low
20.00
Averages
31.67
High
40.00
153.16% Upside
Current: 12.510
Low
20.00
Averages
31.67
High
40.00
Citizens JMP
Jonathan Wolleben
Outperform
maintain
$19 -> $27
2025-07-08
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$19 -> $27
2025-07-08
maintain
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben raised the firm's price target on KalVista to $27 from $19 and keeps an Outperform rating on the shares. Ekterly is poised for a strong launch given the unmet need, clinical profile, and desire from patients for an oral on-demand therapy, though KalVista priced the drug higher than current injectables, which range from ~$4K-$11K per dose and ~$11K-$17K per attack, the analyst tells investors in a research note.
BofA
Buy
upgrade
$22 -> $37
2025-07-08
Reason
BofA
Price Target
$22 -> $37
2025-07-08
upgrade
Buy
Reason
BofA raised the firm's price target on KalVista to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary angioedema attacks with a broad label and no restrictions on type of HAE attack or background LTP usage for patients 12 and older. The firm, which says the approval was in-line with its expectations and it is "encouraged by the broad label," remains "bullish" on Ekterly's differentiation as the only oral on-demand treatment on the market, the analyst tells investors.
H.C. Wainwright
Buy
downgrade
$30 -> $27
2025-07-08
Reason
H.C. Wainwright
Price Target
$30 -> $27
2025-07-08
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on KalVista to $27 from $30 and keeps a Buy rating on the shares. The firm says a recurring concern in its talks with key opinion leaders is the challenge facing KalVista of securing insurance coverage for Ekterly. The leaders would lack a strong clinical argument to justify Ekterly as medically superior if coverage were denied, given the absence of head-to-head data showing superiority over existing on-demand options like icatibant, the analyst tells investors in a research note.
Jefferies
Maury Raycroft
Buy
maintain
$32 -> $40
2025-07-07
Reason
Jefferies
Maury Raycroft
Price Target
$32 -> $40
2025-07-07
maintain
Buy
Reason
Jefferies analyst Maury Raycroft raised the firm's price target on KalVista to $40 from $32 and keeps a Buy rating on the shares after the company announced that the FDA has approved Ekterly for the treatment of acute attacks of hereditary angioedema in adult and pediatric patients. The approval "hit our bull-case" with a broad label, no safety surprises and pricing slightly higher than the firm's "upper-end" estimate, says the analyst, who raised the firm's peak sales estimate to about $700M from a prior forecast of $532M.
Leerink
Joseph P. Schwartz
Outperform
maintain
$18 -> $20
2025-07-07
Reason
Leerink
Joseph P. Schwartz
Price Target
$18 -> $20
2025-07-07
maintain
Outperform
Reason
Leerink analyst Joseph P. Schwartz raised the firm's price target on KalVista to $20 from $18 and keeps an Outperform rating on the shares. The firm notes the FDA approved Ekterly as the first and only on-demand treatment for hereditary angioedema attacks. Leerink believes this is a launch investors will want to own.
Needham
Serge Belanger
Strong Buy
Reiterates
$28
2025-04-08
Reason
Needham
Serge Belanger
Price Target
$28
2025-04-08
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Kalvista Pharmaceuticals Inc (KALV.O) is -3.75, compared to its 5-year average forward P/E of -4.21. For a more detailed relative valuation and DCF analysis to assess Kalvista Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.21
Current PE
-3.75
Overvalued PE
-2.02
Undervalued PE
-6.40
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.29
Current EV/EBITDA
-2.94
Overvalued EV/EBITDA
0.49
Undervalued EV/EBITDA
-1.07
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
174.00
Current PS
18.22
Overvalued PS
700.54
Undervalued PS
-352.55
Financials
Annual
Quarterly
FY2025Q4
N/A
Total Revenue
FY2025Q4
YoY :
+13.57%
-55.03M
Operating Profit
FY2025Q4
YoY :
+16.97%
-52.23M
Net Income after Tax
FY2025Q4
YoY :
-4.85%
-0.98
EPS - Diluted
FY2025Q4
YoY :
+168.46%
-40.88M
Free Cash Flow
FY2025Q4
N/A
Gross Profit Margin - %
FY2025Q4
N/A
FCF Margin - %
FY2025Q4
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 854.52% over the last month.
Sold
0-3
Months
1.1M
USD
3
3-6
Months
366.8K
USD
7
6-9
Months
224.0K
USD
6
0-12
Months
405.2K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
1
235.5K
USD
Months
6-9
8
3.1M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 7382.63% over the last quarter.
Sold
0-3
Months
1.4M
Volume
1
3-6
Months
18.7K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
4
4.1M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 854.52% over the last month.
Sold
0-3
Months
1.1M
USD
3
3-6
Months
366.8K
USD
7
6-9
Months
224.0K
USD
6
0-12
Months
405.2K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
1
235.5K
USD
Months
6-9
8
3.1M
USD
Months
0-12
0
0.0
USD
Months
KALV News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
07:19:00
KalVista confirms maintenance of orphan designation for sebetralstat
2025-07-25 (ET)
2025-07-25
08:03:02
KalVista receives CHMP opinion recommending sebetralstat marketing authorization
2025-07-15 (ET)
2025-07-15
16:07:18
KalVista announces MHRA approval of Ekterly
Sign Up For More Events
Sign Up For More Events
News
9.0
07-25NewsfilterKalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks
9.0
07-25SeekingAlphaKalVista, Biogen, Ionis get EU positive opinions for key drugs
9.0
07-16NASDAQ.COMKalVista Secures UK Approval For EKTERLY, First Oral On-Demand Treatment For Hereditary Angioedema
Sign Up For More News
People Also Watch
CDXS
Codexis Inc
2.800
USD
+1.08%
PKST
Peakstone Realty Trust
11.850
USD
-1.90%
BWMX
Betterware de Mexico SAPI de CV
12.570
USD
-5.98%
DHIL
Diamond Hill Investment Group Inc
143.900
USD
+1.05%
QSI
Quantum-Si Inc
1.200
USD
-5.51%
CELC
Celcuity Inc
46.660
USD
+1.70%
MTRX
Matrix Service Co
14.660
USD
-1.68%
NRC
National Research Corp
15.090
USD
-0.07%
SGU
Star Group LP
11.420
USD
-2.39%
DIN
Dine Brands Global Inc
20.870
USD
-0.90%
FAQ
What is Kalvista Pharmaceuticals Inc (KALV) stock price today?
The current price of KALV is 12.51 USD — it has increased 0.81 % in the last trading day.
What is Kalvista Pharmaceuticals Inc (KALV)'s business?
What is the price predicton of KALV Stock?
What is Kalvista Pharmaceuticals Inc (KALV)'s revenue for the last quarter?
What is Kalvista Pharmaceuticals Inc (KALV)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Kalvista Pharmaceuticals Inc (KALV)'s fundamentals?
How many employees does Kalvista Pharmaceuticals Inc (KALV). have?